复锐医疗科技:直销占比上行至87% 关注肉毒获批节点

方正证券
25 Mar

事件:复锐医疗科技披露2024 年年度业绩:2024 全年:年度收入3.49 亿美元(-2.8%),归母净利润0.25 亿美元(-20.2%);2024 年H2:收入1.80 亿美元(-3.9%),归母净利润0.14 亿美元(+12.5%)。收入拆分:亚太&欧洲贡献核心增长,直销占比持续上行至87%按产品:2024 年①医疗美容收入3.09 亿美元(-2.4%),主要是受北美及拉丁美洲地区医美产品...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10